Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $42.25.

A number of brokerages recently weighed in on VOR. Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price target for the company. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wedbush lifted their price objective on shares of Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Insider Transactions at Vor Biopharma

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 458,411 shares of Vor Biopharma stock in a transaction on Friday, April 17th. The shares were sold at an average price of $16.28, for a total value of $7,462,931.08. Following the transaction, the director directly owned 2,739,208 shares of the company’s stock, valued at approximately $44,594,306.24. The trade was a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 795,524 shares of company stock valued at $12,779,203 over the last 90 days. 0.27% of the stock is currently owned by insiders.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in Vor Biopharma by 28,408.1% during the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after buying an additional 112,496 shares during the last quarter. Irenic Capital Management LP purchased a new stake in Vor Biopharma in the first quarter valued at about $583,000. Renaissance Technologies LLC purchased a new stake in Vor Biopharma in the first quarter valued at about $2,298,000. Sei Investments Co. acquired a new stake in Vor Biopharma in the first quarter worth about $245,000. Finally, Independent Financial Group LLC acquired a new stake in Vor Biopharma in the first quarter worth about $249,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

Shares of NASDAQ:VOR opened at $18.50 on Wednesday. Vor Biopharma has a 52 week low of $6.50 and a 52 week high of $53.00. The firm has a 50 day moving average of $15.85 and a 200 day moving average of $14.95.

Vor Biopharma (NASDAQ:VOR) last posted its earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Equities research analysts predict that Vor Biopharma will post -2.51 EPS for the current year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).